Navigation Links
Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2009 Financial Results
Date:3/3/2010

PALO ALTO, Calif., March 3 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) today announced financial results for the fourth quarter and full year ended December 31, 2009.

Total revenues for the quarter ended December 31, 2009 were $38.3 million, compared to $19.6 million for the quarter ended December 31, 2008. Total revenues for the year ended December 31, 2009 were $128.4 million, compared to $67.5 million for the year ended December 31, 2008. Contract revenues for 2009 of $11.1 million included the recognition of a $10.0 million milestone payment from UCB Pharma Limited received in 2008.

XYREM® (sodium oxybate) oral solution net sales increased 100% to $31.6 million for the quarter ended December 31, 2009, compared to net sales of $15.8 million for the quarter ended December 31, 2008. XYREM net sales for the year ended December 31, 2009 increased 80% to $96.8 million, compared with $53.8 million for the year ended December 31, 2008. Net sales of once-daily LUVOX CR® (fluvoxamine maleate) Extended-Release Capsules, launched in April 2008, increased 86% to $5.7 million for the quarter ended December 31, 2009, compared to $3.1 million for the quarter ended December 31, 2008.  LUVOX CR net sales for the year ended December 31, 2009 increased 220% to $18.3 million, compared with $5.7 million for the year ended December 31, 2008.

"2009 was a tremendous year for Jazz Pharmaceuticals in continuing our mission to help improve patients' lives.  Our sales team delivered outstanding performance in 2009, educating physicians on the appropriate use of our products, which resulted in records for prescriptions of both XYREM and LUVOX CR," said Bob Myers, President of Jazz Pharmaceuticals.

Research and development expenses for the quarter ended December 31, 2009 were $6.3 million, compared to $14.7 million for the quarter ended December 31, 2008.  For the year ended December 31, 2009, research and development expenses were $36.6 million, compared to $70.0 million for the year ended December 31, 2008.  Research and development expenses in both 2009 and 2008 primarily reflect the expenses relating to Phase III clinical activities for the company's JZP-6 product candidate, sodium oxybate for the treatment of fibromyalgia.  In 2009, the company completed the second of two Phase III clinical studies and submitted a New Drug Application (NDA) for JZP-6 to the U.S. Food and Drug Administration (FDA) in December.  The NDA for JZP-6 was filed by the FDA in February 2010 and the target date for the FDA to complete its review under the Prescription Drug User Fee Act (PDUFA) is October 11, 2010.

Selling, general and administrative expenses for the quarter ended December 31, 2009 were $15.7 million, compared to $20.2 million for the quarter ended December 31, 2008.  For the year ended December 31, 2009, selling, general and administrative expenses were $58.7 million, compared to $111.4 million for the year ended December 31, 2008. The decrease in 2009 relative to 2008 was primarily due to reduced numbers of employees and lower marketing and promotional expenses for LUVOX CR, which was launched in 2008.

Jazz Pharmaceuticals' net income for the quarter ended December 31, 2009 was $5.7 million, or $0.17 per diluted share, compared to a net loss of $56.9 million, or $2.04 per share, for the quarter ended December 31, 2008. For the year ended December 31, 2009, the net loss was $6.8 million, or $0.23 per share, compared to a net loss of $184.3 million, or $7.19 per share, for the year ended December 31, 2008.  Contributing to the net loss in 2008 was a fourth quarter non-cash impairment charge of $29.8 million relating to the company's LUVOX CR intangible asset.

Jazz Pharmaceuticals' adjusted net income for the quarter ended December 31, 2009 was $10.8 million, or $0.33 per diluted share.  Adjusted net loss for the year ended December 31, 2009 was $1.5 million, or $0.05 per share.  Adjusted net income/(loss) and adjusted net income/(loss) per diluted share are non-GAAP financial measures that exclude from GAAP net income/(loss) and GAAP net income/(loss) per diluted share revenue related to upfront and milestone payments and gains on sales of product rights, and certain expenses comprised of amortization and impairment of intangible assets, stock-based compensation and interest expense associated with a debt discount and debt issuance costs.  A reconciliation of adjusted net income/(loss) and adjusted net income/(loss) per diluted share to GAAP net income/(loss) and GAAP net income/(loss) per diluted share, respectively is available in a table included at the end of this press release.

Jazz Pharmaceuticals' cash, cash equivalents and marketable securities as of December 31, 2009 totaled $15.6 million, excluding restricted cash of $3.0 million.

Jazz Pharmaceuticals is increasing its full year 2010 guidance for product sales and net income per diluted share, reflecting continued growth in XYREM and LUVOX CR net sales.  Jazz Pharmaceuticals is also reiterating the 2010 guidance on expenses issued in January 2010.

    
    
                                                  2010 Guidance
                                                  ------------- 
    
    - Total product sales                      $148 – $158 million 
         -- Xyrem                              $124 – $130 million
         -- Luvox CR                            $24 –  $28 million
    - Gross margin                             greater than 90%
    - SG&A expenses                             $65 –   $75 million
    - R&D expenses                              $25 –   $35 million
    - GAAP net income per diluted share       $0.27 –  $0.41
    - Adjusted net income per diluted share   $0.80 –  $0.95(1)
    
    (1) A reconciliation to GAAP net income per diluted share is available 
        in a table at the end of this press release
    
    
    

"2009 was a pivotal year for our business," said Bruce Cozadd, Chairman and Chief Executive Officer of Jazz Pharmaceuticals.  "We achieved profitability in the fourth quarter of 2009 and we expect continued profitability in 2010 driven by sales growth and prudent expense management.  We plan to use cash flows from operations in 2010 to amortize a portion of our outstanding senior debt."

Jazz Pharmaceuticals will host an investor conference call and live audio webcast to give a company update, as well as to discuss financial results and guidance, today (March 3, 2010) commencing at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.  The live webcast may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.JazzPharmaceuticals.com.  Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary.  Investors may participate in the conference call by dialing 1-800-591-6923 in the U.S., or 1-617-614-4907 outside the U.S., and entering passcode 79845734.

An archived version of the webcast will be available through March 17, 2010 on the investors section of the Jazz Pharmaceuticals' website at www.JazzPharmaceuticals.com.

About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry.  For further information see www.JazzPharmaceuticals.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements, including, but not limited to, statements related to Jazz Pharmaceuticals' financial performance and growth potential, including 2010 financial guidance and the sufficiency and use of Jazz Pharmaceuticals' cash resources, statements related to Jazz Pharmaceuticals' JZP-6 product candidate, including statements related to future regulatory matters and its potential commercialization, and statements related to the future development of new dosage forms of sodium oxybate.  These forward-looking statements are based on the company's current expectations and inherently involve significant risks and uncertainties.  Jazz Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to: Jazz Pharmaceuticals' ability to increase sales of its XYREM and LUVOX CR products; Jazz Pharmaceuticals' dependence on single source suppliers and manufacturers; the uncertain and time-consuming regulatory approval process for JZP-6; Jazz Pharmaceuticals' ability to successfully market JZP-6 in the U.S. if approved by the FDA for the treatment of fibromyalgia; Jazz Pharmaceuticals' cash flow estimates, the sufficiency of its cash resources and the potential need to raise additional funds; competition, including from potential generic competitors; Jazz Pharmaceuticals' future financial performance and financial position; and those risks detailed from time-to-time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals' Securities and Exchange Commission filings and reports, including in its Registration Statement on Form S-1 (File No. 333-163999) filed by Jazz Pharmaceuticals with the Securities and Exchange Commission on December 23, 2009.  Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

    
    
                            JAZZ PHARMACEUTICALS, INC.                        
                       CONSOLIDATED STATEMENTS OF OPERATIONS                  
                     (In thousands, except per share amounts)                 
                                    (Unaudited)                               
                                                                              
                                                                              
                                        Three Months Ended      Year Ended    
                                           December 31,        December 31,   
                                         ---------------     --------------   
                                         2009      2008      2009       2008  
                                         ----      ----      ----       ----  
     Revenues:                                                                
       Product sales, net              $37,319   $18,880  $115,108    $64,637 
       Royalties, net                      681       431     2,203      1,739 
       Contract revenues                   284       284    11,138      1,138 
                                           ---       ---    ------      ----- 
         Total revenues                 38,284    19,595   128,449     67,514 
     Operating expenses:                                                      
       Cost of product sales             2,782     3,305     9,638     13,924 
       Research and development          6,317    14,689    36,561     69,963 
        Selling, general and                                                  
        administrative                  15,718    20,183    58,652    111,401 
       Intangible asset amortization     2,057     3,374     7,668     12,828 
       Intangible asset impairment           -    29,763         -     29,763 
                                           ---    ------       ---     ------ 
         Total operating expenses       26,874    71,314   112,519    237,879 
                                        ------    ------   -------    ------- 
     Income (loss) from operations      11,410   (51,719)   15,930   (170,365)
       Interest income                       5       134        34      1,834 
       Interest expense                 (5,762)   (5,365)  (22,796)   (19,742)
       Other income (expense), net           -        10        (4)        16 
       Gain on sale of product rights        -         -         -      3,918 
                                           ---       ---       ---      ----- 
     Net income (loss)                  $5,653  $(56,940)  $(6,836) $(184,339)
                                        ======  ========   =======  ========= 
                                                                              
     Net income (loss) per share:                                             
         Basic                           $0.18    $(2.04)   $(0.23)    $(7.19)
                                         =====    ======    ======     ====== 
         Diluted                         $0.17    $(2.04)   $(0.23)    $(7.19)
                                         =====    ======    ======     ====== 
                                                                              
      Weighted-average common shares                                          
      used in computing                                                       
      net income (loss) per share:                                           
         Basic                          31,155    27,948    30,018     25,646 
                                        ======    ======    ======     ====== 
         Diluted                        33,305    27,948    30,018     25,646 
                                        ======    ======    ======     ====== 
    
    
    
                            JAZZ PHARMACEUTICALS, INC.
                           SUMMARY OF PRODUCT SALES, NET
                                   (In thousands)
                                     (Unaudited)
                                                       
                                                           
                                     Three Months Ended   Year Ended   
                                        December 31,      December 31, 
                                     ---------------     ------------- 
                                        2009    2008       2009    2008
                                        ----    ----       ----    ----
    Xyrem                            $31,644 $15,823    $96,763 $53,803
    Luvox CR                           5,675   3,057     18,345   5,728
    Antizol and Antizol-Vet (1)            -       -          -   5,106
                                         ---     ---        ---   -----
    Total                            $37,319 $18,880   $115,108 $64,637
                                     ======= =======   ======== =======
                                                                       
    (1) The Company sold its rights to and interests in Antizol and 
        Antizol-Vet in August 2008.  
    
    
    
                         JAZZ PHARMACEUTICALS, INC.                    
                   CONDENSED CONSOLIDATED BALANCE SHEETS               
                               (In thousands)                          
                                (Unaudited)                            
                                               December 31,  December 31,
                                                   2009          2008 
                                                   ----          ---- 
                     ASSETS                                            
    Current assets:                                                    
      Cash and cash equivalents                  $15,595       $24,903 
      Restricted cash                              2,988         1,913 
      Marketable securities                            -         1,004 
      Accounts receivable                         12,313         6,643 
      Inventories                                  3,426         4,294 
      Prepaid expenses                             1,653         2,366 
      Other current assets                           979         2,876 
                                                     ---         ----- 
        Total current assets                      36,954        43,999 
    Property and equipment, net                    1,124         2,514 
    Intangible assets, net                        29,858        32,526 
    Goodwill                                      38,213        38,213 
    Other long-term assets                         1,247           246 
                                                   -----           --- 
        Total assets                            $107,396      $117,498 
                                                ========      ======== 
                                                                       
     LIABILITIES AND STOCKHOLDERS' DEFICIT                             
    Current liabilities:                                               
      Line of credit                              $9,399        $3,875 
      Accounts payable                             2,158         5,736 
      Accrued liabilities                         14,296        16,491 
      Senior secured notes                        23,759       118,534 
      Purchased product rights liability           4,000        14,000 
      Liability under government settlement        2,954         2,533 
      Deferred revenue                             2,675        12,322 
                                                   -----        ------ 
        Total current liabilities                 59,241       173,491 
    Deferred rent                                     29             - 
    Purchased product rights liability,                                
     noncurrent                                    9,000             - 
    Deferred revenue, noncurrent                  10,191        11,330 
    Liability under government settlement,                             
     noncurrent                                   10,658        13,063 
    Senior secured notes                          91,107             - 
    Common stock subject to repurchase                 -        12,492 
    Total stockholders' deficit                  (72,830)      (92,878)
                                                 -------       ------- 
    Total liabilities and                                              
     stockholders' deficit                      $107,396      $117,498 
                                                ========      ======== 
    
    
    
                           JAZZ PHARMACEUTICALS, INC.                       
              RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES         
                    (In thousands, except per share amounts)                
                                   (Unaudited)                              
                                                                            
                                                                
                                       Three Months Ended    Year Ended     
                                          December 31,       December 31,   
                                       ---------------      -------------   
                                         2009      2008     2009       2008 
                                         ----      ----     ----       ---- 
                                                                            
     GAAP net income (loss)            $5,653  $(56,940) $(6,836) $(184,339)
     Add:                                                                   
       Intangible asset amortization    2,057     3,374    7,668     12,828 
       Intangible asset impairment          -    29,763        -     29,763 
        Stock-based                                                         
        compensation expense            2,448     2,316    5,957      8,106 
       Non-cash interest expense          956       625    2,810      2,060 
     Deduct:                                                                
       Contract revenues                 (284)     (284) (11,138)    (1,138)
        Gain on sale of                                                     
        product rights                      -         -        -     (3,918)
                                          ---       ---      ---     ------ 
     Adjusted net income (loss)       $10,830  $(21,146) $(1,539) $(136,638)
                                      =======  ========  =======  ========= 
                                                                            
      GAAP net income (loss) per                                            
      diluted share                     $0.17    $(2.04)  $(0.23)    $(7.19)
                                        =====    ======   ======     ====== 
      Adjusted net income (loss)                                            
      per diluted share                 $0.33    $(0.76)  $(0.05)    $(5.33)
                                        =====    ======   ======     ====== 
                                                                            
      Shares used in computing GAAP                                         
      and adjusted net                                                      
        income (loss) per diluted                                           
        share amounts                  33,305    27,948   30,018     25,646 
    
    
    
                            JAZZ PHARMACEUTICALS, INC.                
            RECONCILIATION OF GAAP TO NON-GAAP 2010 FINANCIAL GUIDANCE
                      (In millions, except per share amounts)         
                                                                      
     GAAP net income                                            $9-14 
     Add:                                                             
       Intangible asset amortization                                8 
       Stock-based compensation expense                             7 
       Non-cash interest expense                                    4 
     Deduct:                                                          
       Contract revenues                                           (1)
                                                                  --- 
     Adjusted net income                                       $27-32 
                                                               ====== 
                                                                      
     GAAP net income per diluted share                     $0.27-0.41 
     Adjusted net income per diluted share                 $0.80-0.95 
                                                                      
     Shares used in computing GAAP and adjusted net                   
      income per diluted share amounts                             34 
    
    
    

Non-GAAP Financial Measures

To supplement our financial results and financial guidance presented on a GAAP basis, we use the non-GAAP measures adjusted net income/(loss) and adjusted net income/(loss) per diluted share as shown in the tables above.  These measures exclude (1) revenue related to upfront and milestone payments and gains on sales of products, and (2) certain expenses comprised of amortization and impairment of intangible assets, stock-based compensation and interest expense associated with a debt discount and debt issuance costs.  We believe these non-GAAP financial measures are helpful in understanding our past financial performance and our future results are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read in conjunction with our consolidated financial statements prepared in accordance with GAAP. Our management regularly uses these supplemental non-GAAP financial measures internally to understand, manage and evaluate our business and make operating decisions. Compensation of our executives is based in part on the performance of our business based on these non-GAAP measures. In addition, we believe that the use of these non-GAAP measures enhances the ability of investors to compare our results both from period to period and with those of other companies.  Investors should note that adjusted net income/(loss) and adjusted net income/(loss) per diluted share, as used by Jazz Pharmaceuticals, may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by our competitors and other companies.

SOURCE Jazz Pharmaceuticals, Inc.

Back to top

RELATED LINKS
http://www.jazzpharmaceuticals.com

'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
5. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
6. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
7. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
8. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
9. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... 12, 2016  Sequent Medical, Inc. announced today that ... evaluate the safety and effectiveness of the WEB™ Aneurysm ... intracranial aneurysms.  Prof Laurent Spelle , MD, Head ... Paris, France and Principal Investigator of the ... France and Germany.  Although patients with ruptured ...
(Date:2/12/2016)... 2016  OMS Supply, a large provider of oral ... today the recent launching of their new company website. ... features that enhance the user experience and enable practitioners ... --> --> Despite the ... that started in early 2016, they have already made ...
(Date:2/11/2016)... Feb. 11, 2016 - ... in Personalized Medicine and Cancer Therapy. - European ... Diagnostic Testing Markets. - Key Diagnostic Testing Markets. ... Molecular Diagnostics in Genetic Testing. - Molecular Diagnostics ... - Over-the-Counter Diagnostic Products World Markets. - ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... , ... When an Au Pair comes all the way around the world to ... and they are often worried things won’t go well. More often than not, however, they ... Pair of the Year winner’s all commented how their Au Pairs have become a part ...
(Date:2/12/2016)... Los Angeles, CA (PRWEB) , ... February 12, 2016 , ... ... da Vinci-assisted hernia surgeries are beginning to account for a significant portion of hernia ... Dr. Shirin Towfigh of the Beverly Hills Hernia Center notes that this trend has ...
(Date:2/12/2016)... (PRWEB) , ... February 12, ... ... Foundation today announced a new initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to develop the ... partnership will recruit top students from U.S. universities who will draw from ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... 2016 — 1:30 p.m. – 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination ... life cycle of pharmaceutical products, garnering increased attention from all stakeholders in the ...
(Date:2/12/2016)... ... February 12, 2016 , ... Coco Libre, the maker of coconut water ... LA GRAMMY’s Style Lounge Event. Coco Libre will offer musicians and celebrities the company’s ... big event. The invitation-only gifting suite, held this year at the W Hollywood Hotel, ...
Breaking Medicine News(10 mins):